Francisco J Hernandez-Ilizaliturri

Francisco J Hernandez-Ilizaliturri

UNVERIFIED PROFILE

Are you Francisco J Hernandez-Ilizaliturri?   Register this Author

Register author
Francisco J Hernandez-Ilizaliturri

Francisco J Hernandez-Ilizaliturri

Publications by authors named "Francisco J Hernandez-Ilizaliturri"

Are you Francisco J Hernandez-Ilizaliturri?   Register this Author

67Publications

1685Reads

50Profile Views

Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.

Authors:
Megan M Herr Pallawi Torka Yali Zhang Paul K Wallace Joseph D Tario Elizabeth A Repasky George L Chen Christine M Ho Sophia R Balderman Maureen Ross Bruno Paiva Francisco J Hernandez-Ilizaliturri Philip L McCarthy Theresa Hahn

Bone Marrow Transplant 2020 Jan 21;55(1):77-85. Epub 2019 Jun 21.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/s41409-019-0591-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925359PMC
January 2020

Correction: Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.

Authors:
Megan M Herr Pallawi Torka Yali Zhang Paul K Wallace Joseph D Tario Elizabeth A Repasky George L Chen Christine M Ho Sophia R Balderman Maureen Ross Bruno Paiva Francisco J Hernandez-Ilizaliturri Philip L McCarthy Theresa Hahn

Bone Marrow Transplant 2020 Jan;55(1):272

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/s41409-019-0647-5DOI Listing
January 2020

Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

Authors:
Pallawi Torka Mathew Barth Robert Ferdman Francisco J Hernandez-Ilizaliturri

Curr Hematol Malig Rep 2019 Oct;14(5):426-438

Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s11899-019-00542-8DOI Listing
October 2019

Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).

Authors:
Othman S Akhtar Kristopher Attwood Ian Lund Ryan Hare Francisco J Hernandez-Ilizaliturri Pallawi Torka

Leuk Lymphoma 2019 Jul 2;60(7):1650-1655. Epub 2019 Jan 2.

a Department of Medicine , State University of New York at Buffalo , Buffalo , NY , USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1080/10428194.2018.1554862DOI Listing
July 2019

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.

Authors:
Talha Badar Mehdi Hamadani Veronika Bachanova Kami J Maddocks Elvira Umyarova Julio C Chavez Narendranath Epperla Saurabh Chhabra Ana C Xavier Reem Karmali Mohammed Salhab Nishitha Reddy Martha J Glenn Francisco J Hernandez-Ilizaliturri Christopher R Flowers Andrew M Evens Zheng Zhou Frederick Lansigan Stefan K Barta Jonathon B Cohen Timothy S Fenske Luciano J Costa

Leuk Lymphoma 2019 Apr 2;60(4):940-946. Epub 2018 Oct 2.

q Department of Medicine , University of Alabama , Birmingham , AL , USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1080/10428194.2018.1515944DOI Listing
April 2019

Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.

Authors:
Pankit Vachhani Vishala T Neppalli Christopher J Cancino Paul Bogner Charles L Roche Gyorgy Paragh Marcelle A Grassi Francisco J Hernandez-Ilizaliturri

Br J Haematol 2019 02 22;184(4):674-676. Epub 2018 Feb 22.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/bjh.15154DOI Listing
February 2019

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Authors:
James N Gerson Elizabeth Handorf Diego Villa Alina S Gerrie Parv Chapani Shaoying Li L Jeffrey Medeiros Michael I Wang Jonathon B Cohen Oscar Calzada Michael C Churnetski Brian T Hill Yazeed Sawalha Francisco J Hernandez-Ilizaliturri Shalin Kothari Julie M Vose Martin A Bast Timothy S Fenske Swapna Narayana Rao Gari Kami J Maddocks David Bond Veronika Bachanova Bhaskar Kolla Julio Chavez Bijal Shah Frederick Lansigan Timothy F Burns Alexandra M Donovan Nina Wagner-Johnston Marcus Messmer Amitkumar Mehta Jennifer K Anderson Nishitha Reddy Alexandra E Kovach Daniel J Landsburg Martha Glenn David J Inwards Reem Karmali Jason B Kaplan Paolo F Caimi Saurabh Rajguru Andrew Evens Andreas Klein Elvira Umyarova Bhargavi Pulluri Jennifer E Amengual Jennifer K Lue Catherine Diefenbach Richard I Fisher Stefan K Barta

J Clin Oncol 2019 02 7;37(6):471-480. Epub 2019 Jan 7.

1 Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.18.00690DOI Listing
February 2019

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma.

Authors:
Kyle Runckel Matthew J Barth Cory Mavis Juan J Gu Francisco J Hernandez-Ilizaliturri

Blood Adv 2018 12;2(23):3516-3525

Department of Immunology.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/bloodadvances.2018018168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290104PMC
December 2018

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Authors:
Richard T Hoppe Ranjana H Advani Weiyun Z Ai Richard F Ambinder Patricia Aoun Philippe Armand Celeste M Bello Cecil M Benitez Philip J Bierman Robert Chen Bouthaina Dabaja Robert Dean Andres Forero Leo I Gordon Francisco J Hernandez-Ilizaliturri Ephraim P Hochberg Jiayi Huang Patrick B Johnston Mark S Kaminski Vaishalee P Kenkre Nadia Khan Kami Maddocks David G Maloney Monika Metzger Joseph O Moore David Morgan Craig H Moskowitz Carolyn Mulroney Rachel Rabinovitch Stuart Seropian Randa Tao Jane N Winter Joachim Yahalom Jennifer L Burns Ndiya Ogba

J Natl Compr Canc Netw 2018 Mar;16(3):245-254

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.6004/jnccn.2018.0013DOI Listing
March 2018

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.

Authors:
Pallawi Torka Priyank Patel Wei Tan Gregory Wilding Seema A Bhat Myron S Czuczman Kelvin P Lee George Deeb Vishala Neppalli Cory Mavis Paul Wallace Francisco J Hernandez-Ilizaliturri

Clin Lymphoma Myeloma Leuk 2018 01 6;18(1):e51-e60. Epub 2017 Nov 6.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.clml.2017.09.003DOI Listing
January 2018

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.

Authors:
Juan J Gu Anil Singh Kai Xue Cory Mavis Matthew Barth Vivek Yanamadala Peter Lenz Michael Grau Georg Lenz Myron S Czuczman Francisco J Hernandez-Ilizaliturri

Oncotarget 2018 Jan 19;9(3):4020-4033. Epub 2017 Dec 19.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.

View Article

Download full-text PDF

 Source
http://www.oncotarget.com/fulltext/23425
Publisher Site
http://dx.doi.org/10.18632/oncotarget.23425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790518PMC
January 2018

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Authors:
Monika Pilichowska Stefania Pittaluga Judith A Ferry Jessica Hemminger Hong Chang Jennifer A Kanakry Laurie H Sehn Tatyana Feldman Jeremy S Abramson Athena Kritharis Francisco J Hernandez-Ilizaliturri Izidore S Lossos Oliver W Press Timothy S Fenske Jonathan W Friedberg Julie M Vose Kristie A Blum Deepa Jagadeesh Bruce Woda Gaurav K Gupta Randy D Gascoyne Elaine S Jaffe Andrew M Evens

Blood Adv 2017 Dec 11;1(26):2600-2609. Epub 2017 Dec 11.

Division of Hematology/Oncology, Tufts Medical Center, Boston, MA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/bloodadvances.2017009472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728632PMC
December 2017

C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.

Authors:
Narendranath Epperla Kami J Maddocks Mohammed Salhab Julio C Chavez Nishitha Reddy Reem Karmali Elvira Umyarova Veronika Bachanova Cristiana Costa Martha Glenn Oscar Calzada Ana C Xavier Zheng Zhou Nasheed M Hossain Francisco J Hernandez-Ilizaliturri Zeina Al-Mansour Stefan K Barta Saurabh Chhabra Frederick Lansigan Amitkumar Mehta Michael V Jaglal Andrew M Evens Christopher R Flowers Jonathon B Cohen Timothy S Fenske Mehdi Hamadani Luciano J Costa

Cancer 2017 11 27;123(22):4411-4418. Epub 2017 Jul 27.

Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.30895DOI Listing
November 2017

A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.

Authors:
Allison M Winter Daniel J Landsburg Anthony R Mato Krista Isaac Francisco J Hernandez-Ilizaliturri Nishitha Reddy Stephen Smith Mazyar Shadman Mitchell R Smith Paolo Caimi Deepa Jagadeesh Brian T Hill

Blood 2017 Oct;130(14):1676-1679

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2017-05-786988DOI Listing
October 2017

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:
Myron S Czuczman Marek Trněný Andrew Davies Simon Rule Kim M Linton Nina Wagner-Johnston Randy D Gascoyne Graham W Slack Pierre Brousset David A Eberhard Francisco J Hernandez-Ilizaliturri Gilles Salles Thomas E Witzig Pier Luigi Zinzani George W Wright Louis M Staudt Yandan Yang P Mickey Williams Chih-Jian Lih Jacqueline Russo Anjan Thakurta Patrick Hagner Pierre Fustier Dale Song Ian D Lewis

Clin Cancer Res 2017 Aug 5;23(15):4127-4137. Epub 2017 Apr 5.

Divison of Haematology, Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2818DOI Listing
August 2017

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:
Richard T Hoppe Ranjana H Advani Weiyun Z Ai Richard F Ambinder Patricia Aoun Celeste M Bello Cecil M Benitez Karl Bernat Philip J Bierman Kristie A Blum Robert Chen Bouthaina Dabaja Andres Forero Leo I Gordon Francisco J Hernandez-Ilizaliturri Ephraim P Hochberg Jiayi Huang Patrick B Johnston Mark S Kaminski Vaishalee P Kenkre Nadia Khan David G Maloney Peter M Mauch Monika Metzger Joseph O Moore David Morgan Craig H Moskowitz Carolyn Mulroney Matthew Poppe Rachel Rabinovitch Stuart Seropian Mitchell Smith Jane N Winter Joachim Yahalom Jennifer Burns Ndiya Ogba Hema Sundar

J Natl Compr Canc Netw 2017 05;15(5):608-638

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.6004/jnccn.2017.0064DOI Listing
May 2017

Breast Implant-Associated Anaplastic Large Cell Lymphoma (ALCL): A Case Report.

Authors:
Sevan Evren Thaer Khoury Vishalla Neppalli Helen Cappuccino Francisco J Hernandez-Ilizaliturri Prasanna Kumar

Am J Case Rep 2017 May 31;18:605-610. Epub 2017 May 31.

Department of Radiology, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460956PMC
http://dx.doi.org/10.12659/ajcr.903161DOI Listing
May 2017

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.

Authors:
Roxanne C Jewell Thomas J Kipps Jan Dürig Laimonas Griskevicius Stephan Stilgenbauer Lukáš Smolej Jiří Mayer Georg Hess Francisco J Hernandez-Ilizaliturri Swaminathan Padmanabhan-Iyer Lei Fang Nancy Goldstein Michele Gorczyca Ira Gupta Steen Lisby William G Wierda

Leuk Lymphoma 2017 02 7;58(2):348-356. Epub 2016 Jul 7.

o MD Anderson Cancer Center, The University of Texas , Houston , TX , USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1080/10428194.2016.1195497DOI Listing
February 2017

Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.

Authors:
Juan J Gu Gregory P Kaufman Cory Mavis Myron S Czuczman Francisco J Hernandez-Ilizaliturri

Oncotarget 2017 Feb;8(8):12741-12753

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.18632/oncotarget.14405DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355050PMC
February 2017

Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.

Authors:
Kai Xue Juan J Gu Qunling Zhang Xiaojian Liu Jiachen Wang Xiao-Qiu Li Jianfeng Luo Francisco J Hernandez-Ilizaliturri Stanley F Fernandez Myron S Czuczman Junning Cao Xiaonan Hong Ye Guo

Oncotarget 2016 May;7(22):32519-31

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.18632/oncotarget.8685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078030PMC
May 2016

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.

Authors:
Natalie M Czuczman Matthew J Barth Juan Gu Vishala Neppalli Cory Mavis Sarah E Frys Qiang Hu Song Liu Pavel Klener Petra Vockova Myron S Czuczman Francisco J Hernandez-Ilizaliturri

Blood 2016 Mar 16;127(9):1128-37. Epub 2015 Dec 16.

Departments of Medicine and Immunology.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2015-04-640920DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778163PMC
March 2016

EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.

Authors:
Matthew Smonskey Elena Lasorsa Spencer Rosario Jason S Kirk Francisco J Hernandez-Ilizaliturri Leigh Ellis

Oncoscience 2016 29;3(1):21-30. Epub 2016 Jan 29.

Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA; Department of Molecular Pharmacology and Cancer Therapeutics, State University of New York at Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751913PMC
http://dx.doi.org/10.18632/oncoscience.288DOI Listing
March 2016

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Authors:
Kai Xue Juan J Gu Qunling Zhang Cory Mavis Francisco J Hernandez-Ilizaliturri Myron S Czuczman Ye Guo

J Cancer Res Clin Oncol 2016 Feb 28;142(2):379-87. Epub 2015 Aug 28.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00432-015-2026-yDOI Listing
February 2016

Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.

Authors:
Matthew J Barth Cory Mavis Myron S Czuczman Francisco J Hernandez-Ilizaliturri

Clin Cancer Res 2015 Oct 11;21(19):4391-7. Epub 2015 May 11.

Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York. Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685505PMC
October 2015

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

Authors:
Andrew M Evens Jennifer A Kanakry Laurie H Sehn Athena Kritharis Tatyana Feldman Aimee Kroll Randy D Gascoyne Jeremy S Abramson Adam M Petrich Francisco J Hernandez-Ilizaliturri Zeina Al-Mansour Camille Adeimy Jessica Hemminger Nancy L Bartlett Anthony Mato Paolo F Caimi Ranjana H Advani Andreas K Klein Chadi Nabhan Sonali M Smith Jesus C Fabregas Izidore S Lossos Oliver W Press Timothy S Fenske Jonathan W Friedberg Julie M Vose Kristie A Blum

Am J Hematol 2015 Sep;90(9):778-83

Ohio State University, Columbus, Ohio.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/ajh.24082DOI Listing
September 2015

CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.

Authors:
Jorge J Castillo Julio C Chavez Francisco J Hernandez-Ilizaliturri Santiago Montes-Moreno

Expert Rev Hematol 2015 Jun 1;8(3):343-54. Epub 2015 Feb 1.

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, M221, Boston, MA 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1586/17474086.2015.1007862DOI Listing
June 2015

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.

Authors:
Sarah Frys Zachary Simons Qiang Hu Matthew J Barth Juan J Gu Cory Mavis Joseph Skitzki Liu Song Myron S Czuczman Francisco J Hernandez-Ilizaliturri

Br J Haematol 2015 May 23;169(4):506-19. Epub 2015 Feb 23.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/bjh.13318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802357PMC
May 2015

Hodgkin lymphoma, version 2.2015.

Authors:
Richard T Hoppe Ranjana H Advani Weiyun Z Ai Richard F Ambinder Patricia Aoun Celeste M Bello Cecil M Benitez Philip J Bierman Kristie A Blum Robert Chen Bouthaina Dabaja Andres Forero Leo I Gordon Francisco J Hernandez-Ilizaliturri Ephraim P Hochberg Jiayi Huang Patrick B Johnston Nadia Khan David G Maloney Peter M Mauch Monika Metzger Joseph O Moore David Morgan Craig H Moskowitz Carolyn Mulroney Matthew Poppe Rachel Rabinovitch Stuart Seropian Christina Tsien Jane N Winter Joachim Yahalom Jennifer L Burns Hema Sundar

J Natl Compr Canc Netw 2015 May;13(5):554-86

View Article

Download full-text PDF

 Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898052PMC
http://dx.doi.org/10.6004/jnccn.2015.0075DOI Listing
May 2015

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Authors:
Adam M Petrich Mitul Gandhi Borko Jovanovic Jorge J Castillo Saurabh Rajguru David T Yang Khushboo A Shah Jeremy D Whyman Frederick Lansigan Francisco J Hernandez-Ilizaliturri Lisa X Lee Stefan K Barta Shruthi Melinamani Reem Karmali Camille Adeimy Scott Smith Neil Dalal Chadi Nabhan David Peace Julie Vose Andrew M Evens Namrata Shah Timothy S Fenske Andrew D Zelenetz Daniel J Landsburg Christina Howlett Anthony Mato Michael Jaglal Julio C Chavez Judy P Tsai Nishitha Reddy Shaoying Li Caitlin Handler Christopher R Flowers Jonathon B Cohen Kristie A Blum Kevin Song Haowei Linda Sun Oliver Press Ryan Cassaday Jesse Jaso L Jeffrey Medeiros Aliyah R Sohani Jeremy S Abramson

Blood 2014 Oct 26;124(15):2354-61. Epub 2014 Aug 26.

Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

 Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2014-05-57
Publisher Site
http://dx.doi.org/10.1182/blood-2014-05-578963DOI Listing
October 2014

Novel therapeutic strategies for cutaneous T-cell lymphoma in advanced stages.

Authors:
Lillian Kun Francisco J Hernandez-Ilizaliturri Nishitha M Reddy

Semin Hematol 2014 Jan 14;51(1):35-41. Epub 2013 Nov 14.

Division of Hematology/Oncology(,) Vanderbilt-Ingram Cancer Center, Nashville, TN. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1053/j.seminhematol.2013.11.004DOI Listing
January 2014

MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.

Authors:
Juan J Gu Francisco J Hernandez-Ilizaliturri Cory Mavis Natalie M Czuczman George Deeb John Gibbs Joseph J Skitzki Ritesh Patil Myron S Czuczman

Anticancer Drugs 2013 Nov;24(10):1030-8

Departments of aMedicine bImmunology cPathology dSurgical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/CAD.0000000000000008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685502PMC
November 2013

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

Authors:
Andrew M Evens Ranjana Advani Oliver W Press Izidore S Lossos Julie M Vose Francisco J Hernandez-Ilizaliturri Barrett K Robinson Stavroula Otis Liat Nadav Dagan Ramsey Abdallah Aimee Kroll-Desrosiers Jessica L Yarber Jose Sandoval Kelley Foyil Linda M Parker Leo I Gordon Kristie A Blum Christopher R Flowers John P Leonard Thomas M Habermann Nancy L Bartlett

J Clin Oncol 2013 Nov 16;31(32):4132-9. Epub 2013 Sep 16.

Andrew M. Evens, Tufts University School of Medicine, Boston; Aimee Kroll-Desrosiers, University of Massachusetts Medical School, Worcester, MA; Ranjana Advani and Stavroula Otis, Stanford University Medical Center, Stanford, CA; Oliver W. Press and Linda M. Parker, Fred Hutchinson Cancer Research Center, Seattle, WA; Izidore S. Lossos, Liat Nadav Dagan, and Jose Sandoval, University of Miami School of Medicine, Miami, FL; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Francisco J. Hernandez-Ilizaliturri, Roswell Park Cancer Institute, Buffalo; Ramsey Abdallah and John P. Leonard, Weill Cornell Medical College, New York, NY; Barrett K. Robinson, Indiana University School of Medicine, Indianapolis, IN; Jessica L. Yarber and Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; Kristie A. Blum, The Ohio State University, Columbus, OH; Christopher R. Flowers, Emory University, Atlanta, GA; Thomas M. Habermann, Mayo Clinic, Rochester, MN; and Nancy L. Bartlett, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2013.49.8220DOI Listing
November 2013

The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.

Authors:
Juan J Gu Francisco J Hernandez-Ilizaliturri Gregory P Kaufman Natalie M Czuczman Cory Mavis Joseph J Skitzki Myron S Czuczman

Br J Haematol 2013 Sep 4;162(5):657-69. Epub 2013 Jul 4.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/bjh.12452DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760501PMC
September 2013

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.

Authors:
Richard T Hoppe Ranjana H Advani Weiyun Z Ai Richard F Ambinder Patricia Aoun Celeste M Bello Philip J Bierman Kristie A Blum Robert Chen Bouthaina Dabaja Ysabel Duron Andres Forero Leo I Gordon Francisco J Hernandez-Ilizaliturri Ephraim P Hochberg David G Maloney David Mansur Peter M Mauch Monika Metzger Joseph O Moore David Morgan Craig H Moskowitz Matthew Poppe Barbara Pro Jane N Winter Joachim Yahalom Hema Sundar

J Natl Compr Canc Netw 2012 May;10(5):589-97

Stanford Cancer Institute.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.6004/jnccn.2012.0061DOI Listing
May 2012

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.

Authors:
Matthew J Barth Francisco J Hernandez-Ilizaliturri Cory Mavis Ping-Chiao Tsai John F Gibbs George Deeb Myron S Czuczman

Br J Haematol 2012 Feb 9;156(4):490-8. Epub 2011 Dec 9.

Department of Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/j.1365-2141.2011.08966.xDOI Listing
February 2012

Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma.

Authors:
Ping-Chiao Tsai Francisco J Hernandez-Ilizaliturri Naveen Bangia Scott H Olejniczak Myron S Czuczman

Clin Cancer Res 2012 Feb 6;18(4):1039-50. Epub 2012 Jan 6.

Department of Immunology and Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288324PMC
February 2012

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

Authors:
Francisco J Hernandez-Ilizaliturri George Deeb Pier L Zinzani Stefano A Pileri Farhana Malik William R Macon Andre Goy Thomas E Witzig Myron S Czuczman

Cancer 2011 Nov 14;117(22):5058-66. Epub 2011 Apr 14.

Department of Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA.

View Article

Download full-text PDF

 Source
http://doi.wiley.com/10.1002/cncr.26135
Publisher Site
http://dx.doi.org/10.1002/cncr.26135DOI Listing
November 2011

Hodgkin lymphoma.

Authors:
Richard T Hoppe Ranjana H Advani Weiyun Z Ai Richard F Ambinder Celeste M Bello Philip J Bierman Kristie A Blum Bouthaina Dabaja Ysabel Duron Andres Forero Leo I Gordon Francisco J Hernandez-Ilizaliturri Ephraim P Hochberg David G Maloney David Mansur Peter M Mauch Monika Metzger Joseph O Moore David Morgan Craig H Moskowitz Matthew Poppe Barbara Pro Lawrence Weiss Jane N Winter Joachim Yahalom

J Natl Compr Canc Netw 2011 Sep;9(9):1020-58

Stanford Cancer Institute, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.6004/jnccn.2011.0086DOI Listing
September 2011

Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature.

Authors:
Gayatri Vaidyanathan Nuttapong Ngamphaiboon Francisco J Hernandez-Ilizaliturri

Ann Hematol 2011 Aug 1;90(8):955-62. Epub 2011 Feb 1.

Department of Internal Medicine, State University of New York at Buffalo, Elm and Carlton Streets, Buffalo, NY, 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00277-011-1162-yDOI Listing
August 2011

A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.

Authors:
Taimur Sher Sikander Ailawadhi Kena C Miller Debbie Manfredi Margaret Wood Wei Tan Gregory Wilding Myron S Czuczman Francisco J Hernandez-Ilizaliturri Fredrick Hong Raman Sood Saif Soniwala William Lawrence Saad Jamshed Aisha Masood Daniel Iancu Kelvin Lee Asher Chanan-Khan

Br J Haematol 2011 Jul 9;154(1):104-10. Epub 2011 May 9.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/j.1365-2141.2011.08703.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078729PMC
July 2011

Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.

Authors:
Elizabeth A Brem Karen Thudium Sapna Khubchandani Ping-Chiao Tsai Scott H Olejniczak Seema Bhat Wasif Riaz Jenny Gu Arshad Iqbal Ryan Campagna Joy Knight Cory Mavis Paul Hoskin George Deeb John F Gibbs Gerald Fetterly Myron S Czuczman Francisco J Hernandez-Ilizaliturri

Br J Haematol 2011 Jun 15;153(5):599-611. Epub 2011 Apr 15.

Department of Medicine, Roswell Park Cancer Institute,Elm and Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/j.1365-2141.2011.08669.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092002PMC
June 2011

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

Authors:
William G Wierda Thomas J Kipps Jan Dürig Laimonas Griskevicius Stephan Stilgenbauer Jirí Mayer Lukás Smolej Georg Hess Rasa Griniute Francisco J Hernandez-Ilizaliturri Swaminathan Padmanabhan Michele Gorczyca Chai-Ni Chang Geoffrey Chan Ira Gupta Tina G Nielsen Charlotte A Russell

Blood 2011 Jun 15;117(24):6450-8. Epub 2011 Apr 15.

The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

View Article

Download full-text PDF

 Source
http://www.bloodjournal.org/content/117/24/6450.full.pdf
Web Search
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-12-32
Publisher Site
http://dx.doi.org/10.1182/blood-2010-12-323980DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916561PMC
June 2011

The emerging role of lenalidomide in the management of lymphoid malignancies.

Authors:
Francisco J Hernandez-Ilizaliturri Sameer A Batoo

Ther Adv Hematol 2011 Feb;2(1):45-53

Medical Oncology and Immunology, Roswell Park Cancer Institute (RPCI), Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1177/2040620710390547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573391PMC
February 2011

Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.

Authors:
Scott H Olejniczak Jennifer Blickwedehl Alan Belicha-Villanueva Naveen Bangia Wasif Riaz Cory Mavis James L Clements John Gibbs Francisco J Hernandez-Ilizaliturri Myron S Czuczman

Blood 2010 Dec 7;116(25):5605-14. Epub 2010 Oct 7.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2009-12-259754DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031407PMC
December 2010

Novel disease targets and management approaches for diffuse large B-cell lymphoma.

Authors:
Wyndham H Wilson Francisco J Hernandez-Ilizaliturri Kieron Dunleavy Richard F Little Owen A O'Connor

Leuk Lymphoma 2010 Aug;51 Suppl 1:1-10

Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.3109/10428194.2010.500045DOI Listing
August 2010

Diffuse large B-cell lymphoma presenting as pancoast tumor.

Authors:
Nuttapong Ngamphaiboon Sulada Pukiat Yugandhar Kandimalla Francisco J Hernandez-Ilizaliturri James J Rooney

J Clin Oncol 2010 Jun 12;28(16):e254-6. Epub 2010 Apr 12.

Department of Medicine, Roswell Park Cancer Institute, University of Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://jco.ascopubs.org/content/28/16/e254.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009.26.1925
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.26.1925DOI Listing
June 2010

Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms.

Authors:
Wasif Riaz Francisco J Hernandez-Ilizaliturri Myron S Czuczman

Immunol Res 2010 Mar;46(1-3):192-205

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/content/pdf/10.1007/s12026-009-8121
Web Search
http://link.springer.com/10.1007/s12026-009-8121-x
Publisher Site
http://dx.doi.org/10.1007/s12026-009-8121-xDOI Listing
March 2010

Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.

Authors:
Sapna Khubchandani Myron S Czuczman Francisco J Hernandez-Ilizaliturri

Curr Opin Investig Drugs 2009 Jun;10(6):579-87

Roswell Park Cancer Institute, Department of Medicine and Immunology, Elm and Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
June 2009

Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies.

Authors:
Francisco J Hernandez-Ilizaliturri Myron S Czuczman

Oncology (Williston Park) 2009 Jun;23(7):610-5

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

View Article

Download full-text PDF

 Source
http://ac.els-cdn.com/S0305737214001455/1-s2.0-S030573721400
Web Search
http://search.proquest.com/openview/2a11a7c394c553593a6a3c7b
Web Search
June 2009

Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.

Authors:
Francisco J Hernandez-Ilizaliturri Myron S Czuczman

Oncology (Williston Park) 2009 May;23(6):546-53

Lymphoma/Myeloma Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.

View Article

Download full-text PDF

 Source
May 2009

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.

Authors:
Hans-Peter Gerber May Kung-Sutherland Ivan Stone Carol Morris-Tilden Jamie Miyamoto Renee McCormick Stephen C Alley Nicole Okeley Brad Hayes Francisco J Hernandez-Ilizaliturri Charlotte F McDonagh Paul J Carter Dennis Benjamin Iqbal S Grewal

Blood 2009 Apr 15;113(18):4352-61. Epub 2009 Jan 15.

Department of Preclinical Therapeutics, Seattle Genetics, Bothell, WA 98021, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2008-09-179143DOI Listing
April 2009

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.

Authors:
David M Goldenberg Edmund A Rossi Rhona Stein Thomas M Cardillo Myron S Czuczman Francisco J Hernandez-Ilizaliturri Hans J Hansen Chien-Hsing Chang

Blood 2009 Jan 21;113(5):1062-70. Epub 2008 Oct 21.

Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2008-07-168146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635072PMC
January 2009

The use of galiximab in non-Hodgkin lymphoma.

Authors:
Sanjay Vinjamaram Myron S Czuczman Francisco J Hernandez-Ilizaliturri

Clin Lymphoma Myeloma 2008 Oct;8(5):277-82

Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14202, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.3816/CLM.2008.n.038DOI Listing
October 2008

Hodgkin disease/lymphoma.

Authors:
Richard T Hoppe Ranjana Hira Advani Richard F Ambinder Philip J Bierman Clara D Bloomfield Kristie Blum Bouthaina Dabaja Benjamin Djulbegovic Andres Forero Leo I Gordon Francisco J Hernandez-Ilizaliturri Melissa M Hudson Mark S Kaminski Gena Love David G Maloney David Mansur Peter M Mauch Joseph O Moore Russell J Schilder Lawrence M Weiss Jane N Winter Joachim Yahalom Andrew D Zelenetz

J Natl Compr Canc Netw 2008 Jul;6(6):594-622

Stanford Comprehensive Cancer Center, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.6004/jnccn.2008.0046DOI Listing
July 2008

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.

Authors:
Scott H Olejniczak Francisco J Hernandez-Ilizaliturri James L Clements Myron S Czuczman

Clin Cancer Res 2008 Mar;14(5):1550-60

Departments of Immunology and Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1255DOI Listing
March 2008

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.

Authors:
Myron S Czuczman Scott Olejniczak Aruna Gowda Adam Kotowski Arvinder Binder Harman Kaur Joy Knight Petr Starostik Julie Deans Francisco J Hernandez-Ilizaliturri

Clin Cancer Res 2008 Mar;14(5):1561-70

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

View Article

Download full-text PDF

 Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-1254DOI Listing
March 2008

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

Authors:
Nishitha Reddy Francisco J Hernandez-Ilizaliturri George Deeb Mark Roth Mary Vaughn Joy Knight Paul Wallace Myron S Czuczman

Br J Haematol 2008 Jan 9;140(1):36-45. Epub 2007 Nov 9.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.
Web Search
https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.
Web Search
http://doi.wiley.com/10.1111/j.1365-2141.2007.06841.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2141.2007.06841.xDOI Listing
January 2008

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.

Authors:
Raymond I Cruz Francisco J Hernandez-Ilizaliturri Scott Olejniczak George Deeb Joy Knight Paul Wallace Beth L Thurberg William Kennedy Myron S Czuczman

Leuk Lymphoma 2007 Dec;48(12):2424-36

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1080/10428190701647879DOI Listing
December 2007

Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

Authors:
Sreeram Maddipatla Francisco J Hernandez-Ilizaliturri Joy Knight Myron S Czuczman

Clin Cancer Res 2007 Aug;13(15 Pt 1):4556-64

School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0680DOI Listing
August 2007

Hodgkin disease/lymphoma. Clinical practice guidelines in oncology.

Authors:
Richard T Hoppe Ranjana Hira Advani Philip J Bierman Clara D Bloomfield Francis Buadi Benjamin Djulgegovic Andres Forero Leo I Gordon Francisco J Hernandez-Ilizaliturri Mark S Kaminski Gena Love David G Maloney Peter M Mauch Joseph O Moore Russell J Schilder Lawrence Weiss Jane N Winter Joachim Yahalom Andrew D Zelenetz

J Natl Compr Canc Netw 2006 Mar;4(3):210-30

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.6004/jnccn.2006.0021DOI Listing
March 2006

Primary esophageal lymphoma: case series and review of the literature.

Authors:
Krishdeep Singh Chadha Francisco J Hernandez-Ilizaliturri Milind Javle

Dig Dis Sci 2006 Jan;51(1):77-83

Department of Internal Medicine, School of Medicine, State University of New York at Buffalo, Buffalo, New York 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10620-006-3088-0DOI Listing
January 2006

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.

Authors:
Francisco J Hernandez-Ilizaliturri Venkata Jupudy Scott Reising Elizabeth A Repasky Myron S Czuczman

Leuk Lymphoma 2005 Dec;46(12):1775-84

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1080/17402520500182329DOI Listing
December 2005

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.

Authors:
Francisco J Hernandez-Ilizaliturri Nishitha Reddy Beata Holkova Edris Ottman Myron S Czuczman

Clin Cancer Res 2005 Aug;11(16):5984-92

Department of Medicine , Roswell Park Cancer Institute Buffalo, New York 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0577DOI Listing
August 2005

Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.

Authors:
Jeyanthi Ramanarayanan Francisco J Hernandez-Ilizaliturri Asher Chanan-Khan Myron S Czuczman

Br J Haematol 2004 Dec;127(5):519-30

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/j.1365-2141.2004.05239.xDOI Listing
December 2004

Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.

Authors:
Francisco J Hernandez-Ilizaliturri Aruna Gowda Myron S Czuczman

Clin Adv Hematol Oncol 2004 Sep;2(9):606-18

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
September 2004

Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience.

Authors:
Francisco J Hernandez-Ilizaliturri Dongfeng Tan David Cipolla Gregory Connolly George Debb Nithya Ramnath

Am J Clin Oncol 2004 Feb;27(1):68-72

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/01.coc.0000046301.83671.09DOI Listing
February 2004

Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.

Authors:
Francisco J Hernandez-Ilizaliturri Venkata Jupudy Julie Ostberg Ezogelin Oflazoglu Amy Huberman Elizabeth Repasky Myron S Czuczman

Clin Cancer Res 2003 Dec;9(16 Pt 1):5866-73

Department of Medicine, Roswell Park Cancer Institute Buffalo, New York 14263, USA.

View Article

Download full-text PDF

 Source
December 2003